Monoamine Oxidase Inhibitors (MAOIs) in psychiatric practice: how to use them safely and effectively
Monoamine Oxidase Inhibitors (MAOIs) in psychiatric practice: how to use them safely and effectively
Monoamine oxidase inhibitors (MAOIs) were among the first licensed pharmacological treatments for patients with depression, but over time have fallen out of mainstream clinical use. This has led to a loss of clinician training opportunities and reduced availability of MAOIs for prescribing. This article provides a concise and practical overview of how to use MAOIs safely and effectively in psychiatric practice. We consider the history of MAOIs, why they are not used more frequently, their mechanisms of action, availability, indications and efficacy, general tolerability, withdrawal symptoms, and safety considerations (including hypertensive reactions and serotonin syndrome). Practical advice is given in terms of dietary restrictions, interactions with other medications (both prescribed and non-prescribed), and how prescribers can stop and switch MAOIs, both within the drug class and outside of it. We also provide advice on choice of MAOI and treatment sequencing. Lastly we consider emerging directions and potential additional indications.
703–716
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
July 2021
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Chamberlain, Samuel R. and Baldwin, David S.
(2021)
Monoamine Oxidase Inhibitors (MAOIs) in psychiatric practice: how to use them safely and effectively.
CNS drugs, 36 (1), .
(doi:10.1007/s40263-021-00832-x).
Abstract
Monoamine oxidase inhibitors (MAOIs) were among the first licensed pharmacological treatments for patients with depression, but over time have fallen out of mainstream clinical use. This has led to a loss of clinician training opportunities and reduced availability of MAOIs for prescribing. This article provides a concise and practical overview of how to use MAOIs safely and effectively in psychiatric practice. We consider the history of MAOIs, why they are not used more frequently, their mechanisms of action, availability, indications and efficacy, general tolerability, withdrawal symptoms, and safety considerations (including hypertensive reactions and serotonin syndrome). Practical advice is given in terms of dietary restrictions, interactions with other medications (both prescribed and non-prescribed), and how prescribers can stop and switch MAOIs, both within the drug class and outside of it. We also provide advice on choice of MAOI and treatment sequencing. Lastly we consider emerging directions and potential additional indications.
Text
BaldCham-MAOI-Revision-June2021-hide
- Accepted Manuscript
Text
Chamberlain-Baldwin-MAOI
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 27 May 2021
e-pub ahead of print date: 9 July 2021
Published date: July 2021
Additional Information:
A correction has been attached to this output located at
https://doi.org/10.1007/s40263-021-00880-3 and https://link.springer.com/article/10.1007/s40263-021-00880-3
Identifiers
Local EPrints ID: 449630
URI: http://eprints.soton.ac.uk/id/eprint/449630
ISSN: 1172-7047
PURE UUID: a202560f-78bb-4ded-8108-fe413a56fbc2
Catalogue record
Date deposited: 09 Jun 2021 16:31
Last modified: 12 Jul 2024 04:06
Export record
Altmetrics
Contributors
Author:
Samuel R. Chamberlain
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics